drugset / Trial / NCT00156884
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
Phase 2
Completed
58 enrolled
Alberta Health services
Amersham Health · collabThe Prostate Cancer Research Foundation of Canada · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Timeline
- Start
- 2003-08
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | strontium-89 | Other / unclassified | — | — |